Correlation between PD-L1 expression and
MET amplification
PD-L1
non-small cell lung cancer
oncogenic driver
smoking habit
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
31
05
2021
accepted:
28
07
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Non-small cell lung cancers (NSCLC) are the most common type of lung cancer and can be classified according to the presence of mutually exclusive oncogenic drivers. The majority of NSCLC patients present a non-actionable oncogenic driver, and treatment resistance through the amplification of the
Identifiants
pubmed: 34504652
doi: 10.18632/oncotarget.28045
pii: 28045
pmc: PMC8416561
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1802-1810Informations de copyright
Copyright: © 2021 Domènech et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
Références
Oncotarget. 2018 Feb 8;9(17):13682-13693
pubmed: 29568386
Lung Cancer. 2015 Aug;89(2):181-8
pubmed: 26024796
Cancer. 2019 Apr 1;125(7):1038-1049
pubmed: 30548240
Curr Oncol Rep. 2019 Feb 26;21(3):21
pubmed: 30806814
Eur Neurol. 2009;61(2):65-8
pubmed: 19039223
Curr Treat Options Oncol. 2014 Dec;15(4):644-57
pubmed: 25228144
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
J Clin Oncol. 2017 Dec 1;35(34):3867-3876
pubmed: 29053400
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
Mod Pathol. 2020 Jan;33(1):109-117
pubmed: 31383957
Lung Cancer Manag. 2020 Jul 24;9(3):LMT36
pubmed: 32774467
Crit Rev Oncol Hematol. 2016 May;101:75-85
pubmed: 26969107
J Immunother. 2018 Jul/Aug;41(6):292-299
pubmed: 29683890
Cancer Biol Ther. 2016 Apr 2;17(4):407-13
pubmed: 26954523
Eur J Surg Oncol. 2015 Apr;41(4):450-6
pubmed: 25682184
Br J Cancer. 2019 Mar;120(5):527-536
pubmed: 30723303
Thorac Cancer. 2019 Jan;10(1):103-110
pubmed: 30475455
Clin Lung Cancer. 2016 Jul;17(4):263-270.e2
pubmed: 26707383
Oncotarget. 2018 Feb 7;9(16):12959-12970
pubmed: 29560123
J Thorac Oncol. 2016 Aug;11(8):1293-1304
pubmed: 27262212
Sci Rep. 2017 Aug 31;7(1):10255
pubmed: 28860576
ESMO Open. 2018 Oct 2;3(6):e000406
pubmed: 30305940
PLoS One. 2014 Sep 18;9(9):e107677
pubmed: 25232729
Nat Rev Clin Oncol. 2020 Sep;17(9):569-587
pubmed: 32514147
Cancer Epidemiol. 2016 Oct;44:203-221
pubmed: 27460784
Oncotarget. 2017 Aug 4;8(40):68221-68229
pubmed: 28978110
Lung Cancer. 2019 Jul;133:96-102
pubmed: 31200835
Clin Pharmacol Ther. 2017 Nov;102(5):757-764
pubmed: 28786099
Transl Oncol. 2016 Feb;9(1):64-69
pubmed: 26947883
Br J Cancer. 2015 Jan 6;112(1):95-102
pubmed: 25349974
Cancers (Basel). 2014 Jul 22;6(3):1540-52
pubmed: 25055117
Am J Respir Crit Care Med. 2013 Oct 1;188(7):770-5
pubmed: 23841470
Clin Cancer Res. 2018 Sep 15;24(18):4579-4587
pubmed: 29898990